On-demand Webinar

De-risking CDX Models in Humanized Mice

Our expert-led webinar explores how PBMC-humanized models can accelerate the development of next-generation immunotherapies. We share best practices and real world applications that help you generate predictive, high-value data and reduce the risks of clinical translation.

Watch a preview:

What you’ll Learn:

How to optimize donor screening: Discover how PBMC donor screening assays can be applied to identify the most suitable donors and enhance model performance.
How to minimize variability: Gain insight into donor selection strategies that reduce graft vs. tumor (GvT) effect and deliver more reliable results.
How to unlock translational insights: See how CDX models in PBMC-humanized mice provide a powerful platform for evaluating drug efficacy, guiding biomarker discovery, and supporting regulatory packages.

About The Presenter:

Dean O. Campbell, PhD, Senior Director, Scientific Engagement and Consultancy, Crown Bioscience

Dr. Campbell is a trained cancer biologist with expertise in molecular imaging, pharmacology, preclinical cancer therapeutics and in vivo models.

Dr. Campbell earned his PhD in Biochemistry and Molecular Biology from the University of Georgia. He then completed his postdoctoral training in the department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). At UCLA, he worked on developing PET imaging probes up to first-in-human-trials, and developing small molecule inhibitors for cancer. After UCLA, he joined the in vivo Pharmacology department at Agensys (an affiliate of Astellas Inc.) where he was a Principal Scientist. At Astellas, he worked on developing anti-cancer antibody-drug conjugates (ADCs), CD3 bispecifics and antibody-based PET probes. He also worked extensively with humanized mouse models (CD34+- and PBMC-engrafted), with both CDX and PDX models.

At Crown, Dr. Campbell is one of the company’s lead scientific consultants who help scientists and researchers with challenges in their preclinical drug development. He also serves as the first line of scientific support for clients when engaging in new and existing opportunities with our business development teams.